Innovate UK

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

Nuclera specializes in providing a protein prototyping system designed to enhance drug discovery by making proteins readily accessible to researchers. The company's eProtein Discovery system enables scientists to quickly produce and evaluate proteins, thus accelerating their research efforts. Nuclera's automated platform delivers reliable, high-quality, and soluble proteins within a specified timeframe, facilitating the scale-up of protein projects. The integration of technology, including cell-free protein synthesis and digital microfluidics on smart cartridges, allows for efficient, high-throughput access to proteins. This streamlined approach supports researchers in advancing their protein projects more rapidly and effectively.

AgriSound is an agri-tech company that specializes in advanced sound analysis for monitoring insect activity, particularly focusing on pollinators. The company has developed a pollination management platform that utilizes sound, environmental, and vision technology sensors to monitor and predict pollinator behavior across agricultural estates. This platform enables users, including beekeepers, farmers, and researchers, to assess hive status in near real-time through the use of predictive algorithms. By providing insights into insect activity and environmental changes affecting pollination, AgriSound's technology allows for remote management of beehives and supports timely decision-making. This innovation aims to enhance agricultural operations and promote biodiversity by suggesting appropriate actions to maintain optimal pollination conditions.

Fuse Diagnostics focuses on manufacturing diagnostic products that deliver lab-quality information across various sectors. The company aims to provide innovative and cost-effective testing solutions that ensure laboratory accuracy for applications in food and water testing, bioprocessing, and cell biology research. By offering low-cost test kits equipped with integrated readout technology, Fuse Diagnostics enables businesses to obtain rapid and reliable results, thereby enhancing the accessibility and efficiency of diagnostic testing.

LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.

Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.

BSF Enterprise is focused on advancing biotechnology solutions through a strategic approach of acquiring businesses within the biotech, marketing, and e-commerce sectors. The company specializes in cell-based tissue engineering, which enables the development of lab-grown products such as cultured meat, lab-grown leather, human corneas, collagen, and skin substitutes. By leveraging these innovative technologies, BSF Enterprise aims to facilitate sustainable solutions across multiple industries, contributing to significant advancements in the field of biotechnology.

Presymptom Health develops a portfolio of clinical decision support algorithms and blood tests to enable early intervention and transform critical care outcomes.

IXICO is a UK-based company specializing in clinical trial services and technology focused on imaging endpoints for the pharmaceutical and biotechnology sectors. The company primarily operates in the fields of oncology and neurology, offering end-to-end imaging services that cater to various therapeutic areas, including Alzheimer's, Parkinson's, Huntington's disease, and other neurodegenerative conditions. IXICO supports clients throughout the entire clinical research journey, providing services for early and late-phase clinical development, post-marketing assessments, and consultancy. With a presence in multiple countries, including the United States, Switzerland, the Netherlands, and Ireland, IXICO collaborates with pharmaceutical companies, academia, and medical charities to advance the treatment of complex diseases.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.

Aelius Biotech specializes in creating advanced models of the mucosal surfaces of the human body. The company focuses on developing systems that simulate the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract. Aelius Biotech's model gut system allows healthcare industry participants to simulate essential processes such as digestion, mucus permeation, and epithelial absorption. The company provides a range of testing services, including in vitro and in vivo assessments, simple lab assays, and integrated model gut testing across the aerodigestive tract. Additionally, Aelius Biotech conducts human trials, aiding healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

PulmoBiomed is a developer of innovative sampling technology that offers a non-invasive method for clinicians and researchers to collect biological samples. The company's primary product is a passive fluid aerosol sampler designed to capture exhaled breath condensate and environmental particles, effectively segregating them by size. This technology addresses critical challenges in sample collection, such as preventing contamination and loss, while ensuring the generation of highly reproducible data with digital molecular precision. By focusing on metabolomic profiling and biological agent capture, PulmoBiomed aims to enhance the accuracy and reliability of respiratory diagnostics and research.

Mesenbio is a preclinical biopharmaceutical company located at the University of York, specializing in cell-derived therapies. It employs a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which enhances the development of treatments by addressing common challenges in extracellular vesicle therapy. The company is focused on creating innovative treatments for conditions such as arthritis, utilizing engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio aims to improve access to effective therapies for musculoskeletal diseases, thereby contributing to advancements in medical treatment.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

CellRev is a biotechnology company specializing in innovative bioprocessing technologies aimed at improving cell manufacturing for various applications, including cultured meat, cell therapy, and biologics. The company's proprietary technology enables a shift from traditional batch processing to continuous processing of adherent cells, significantly enhancing yield while reducing operating costs and capital expenditures. CellRev's unique cell detachment process, combined with a specially designed bioprocess, addresses critical challenges in manufacturing, such as cell aggregation, clumping, and detachment. This approach allows cell-based vaccine and therapy developers to streamline their production processes, eliminate serum usage, and overcome significant bottlenecks in the industry.

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

PES Technologies specializes in developing advanced technology for soil health analysis. The company has created a microbe sensor that monitors the biological properties of soil, enabling farmers and agronomists to assess the health of their soil effectively. By analyzing the status of microbial activity, the sensor provides insights into long-term changes in soil health resulting from agricultural practices. This innovative tool equips users with the necessary data to make informed decisions regarding soil management, ultimately enhancing agricultural productivity and sustainability.

PES Technologies specializes in developing advanced technology for soil health analysis. The company has created a microbe sensor that monitors the biological properties of soil, enabling farmers and agronomists to assess the health of their soil effectively. By analyzing the status of microbial activity, the sensor provides insights into long-term changes in soil health resulting from agricultural practices. This innovative tool equips users with the necessary data to make informed decisions regarding soil management, ultimately enhancing agricultural productivity and sustainability.

Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.

Carbogenics Ltd is a company based in Edinburgh, United Kingdom, specializing in the development and production of sustainable fertilizers and bio-additives. Established in 2016, Carbogenics has created an innovative process that transforms disposable coffee cups and other non-recyclable paper waste into a carbon-rich material, known as CreChar. This product serves as a carbon additive that enhances biogas production in anaerobic digestion and improves plant growth, ultimately benefiting farmers by increasing crop yields and profitability. In addition to its product offerings, Carbogenics also provides consultancy and analytical services to operators in the anaerobic digestion and wastewater treatment sectors, addressing customer inquiries through various communication channels.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

Intellegens specializes in applying artificial intelligence and machine learning to enhance innovation in various fields, including materials, chemicals, and manufacturing. The company’s flagship software, Alchemite™, originated from research at the University of Cambridge and is designed to train deep neural networks using sparse and noisy data, where conventional methods often struggle. By utilizing Alchemite™, users can conduct analyses through a user-friendly web interface and leverage advanced graphical tools, which streamline the integration of AI into existing workflows and tools. This capability allows clients to achieve significant improvements, such as reducing the number of required experiments by up to 90%, thereby saving time and costs. Intellegens has successfully implemented its technology in diverse applications, including drug discovery, materials development, and manufacturing processes, enabling clients to extract greater value from incomplete datasets.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Corryn Biotechnologies is a biotechnology company focused on innovating wound care solutions through its Heals device, which offers a contactless method for treating chronic and complex wounds. The company has developed advanced applicators that utilize electrical voltages to extrude fine fibers from various fluids, creating wound dressings that can be made from synthetic or natural materials. These dressings can be enhanced with or without active ingredients and are designed to deposit non-woven meshes for effective Advanced Tissue Repair (ATR). Through this technology, Corryn aims to improve the management and healing of chronic wounds, providing a novel approach to wound dressing.

We are a team of matrix biologists, cancer scientists, toxicologists, and biomaterial engineers who have worked together to develop an innovative, animal-free solution for 3D cell culture. We have done this with the support of the NC3Rs, BBSRC, and EPSRC. By combining the skills and expertise of individuals across a broad range of scientific backgrounds we are able to develop technologies that address a variety of unmet challenges in 3D in vitro modelling. Our mission is to provide researchers a better way to model development and disease that is more reproducible, reliable, and ethical. To learn more, visit www.peptimatrix.com

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

PfBIO offers effective alternatives to agrochemicals. PfBIO sifts nature for agricultural allies.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Autolomous Ltd, founded in 2019 and based in Mayfair, United Kingdom, specializes in developing software solutions for manufacturers of cell and gene therapies. Its flagship platform, autoloMATE®, is a cloud-native system that provides comprehensive support for Advanced Therapies and Vector manufacturing processes. The software facilitates the scheduling of patient cell collections, the transport of these cells to production sites, and the tracking of manufacturing processes to ensure compliance with regulatory standards. It also supports the legal release and timely delivery of patient-specific medicines. The highly configurable platform allows clients to customize workflows and integrates seamlessly with existing systems. Autolomous emphasizes data security by utilizing blockchain technology to maintain the integrity of manufacturing data. The company adheres to strict regulatory guidelines and has achieved several ISO certifications, reflecting its commitment to quality management and environmental standards.

Orthonika Limited, established in 2014 and based in London, United Kingdom, specializes in the development and manufacturing of MenisciKnit, an anatomical meniscus replacement designed to address severe meniscus injuries. These injuries can significantly impair mobility and lead to complications such as osteoarthritis and the need for knee arthroplasty. Current treatment options, including partial meniscectomy and allograft transplantation, often fall short, leaving a significant unmet need in the market. MenisciKnit employs a unique fiber-reinforced material structure that closely mimics the natural meniscus, aiming to restore proper knee biomechanics. This innovative approach not only provides a solution for those with severe meniscus damage but also supports patients in resuming active lifestyles and offers a comprehensive alternative to traditional knee-related treatments.

Hexis Lab is a biotechnology company focused on the research and development of innovative natural skincare solutions tailored for diverse skin types globally. The company utilizes a discovery platform that combines big data cloud computing and in-silico computer modeling to analyze a comprehensive database of plant-derived compounds. This approach allows Hexis Lab to identify effective ingredients aimed at protecting and repairing sun-damaged skin while enhancing overall well-being. By employing proprietary AI techniques, Hexis Lab accelerates the development process for clients in the beauty, skincare, personal care, nutraceuticals, and pharmaceutical sectors, facilitating the identification of novel ingredients and formulation strategies.

ScubaTx focuses on developing an organ preservation system that utilizes the Persufflation method, which is known for its effectiveness in preserving organs during transportation. By enhancing the condition of grafts during preservation, ScubaTx enables healthcare providers to expand the availability of viable organs for transplantation. The company aims to improve organ preservation practices through innovative software design, ultimately delivering significant cost savings to healthcare providers. This advancement not only enhances the quality of organ transplants but also contributes to increasing the overall supply of life-saving organs available to patients in need.

Lindus Health is a clinical research organization focused on delivering comprehensive clinical trial services for health and biotech companies. The company offers a range of solutions, including ethics and IRB submission, trial monitoring, data management, biostatistics, regulatory support, and payer affairs. By utilizing a proprietary software platform, Lindus Health automates various aspects of the clinical trial workflow, which streamlines operations and minimizes manual inefficiencies. This platform also facilitates access to electronic health records, enhancing patient recruitment and clinical data capture. Furthermore, Lindus Health leverages real-world patient data to improve trial design and execution, ultimately aiming to accelerate the clinical trial process while reducing risks and costs associated with trial failures.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

Flybox® is an Insect Waste Management (IWM) company delivering innovative insect bioconversion technology and expert support to revolutionise waste management. Flybox® provides tailored IWM solutions for established waste and food businesses, alongside a streamlined breeding and monetisation service that simplifies startup and scaling for new operators. Its modular IWM systems integrate seamlessly with existing waste infrastructure, allowing businesses to transform organic waste streams and byproducts into valuable proteins and fertilisers. With patented technology and a steadfast commitment to circular economy principles, Flybox® is advancing global efforts to reduce landfill dependency, minimise reliance on deforestation-linked soy, and enhance food security. Headquartered in the UK and active internationally, Flybox® is a leader in sustainable waste solutions, driving positive change across agriculture, waste management, and environmental resilience.

Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

DeepMirror is a software platform that integrates human expertise with artificial intelligence to enhance drug discovery processes. The company specializes in predicting the properties of molecules and their affinity for various targets, thereby streamlining the research and development efforts of biopharmaceutical teams. By employing structured perception and feature fusion techniques, DeepMirror's platform delivers advanced 3D insights while maintaining low power consumption. This capability simplifies the analysis of complex data, ultimately allowing researchers to focus on the most promising drug candidates and conduct fewer experiments, leading to more efficient drug development.

Kelpi is a sustainable biotech start-up focused on bio-refining seaweed to create innovative bioplastic packaging solutions. The company develops a thin bio-plastic coating for paper and cardboard, replacing traditional fossil fuel-based plastics used in packaging for food, beverages, cosmetics, and personal care products. This coating is derived from renewable feedstocks, primarily compostable seaweed, and has been certified as recyclable. By utilizing marine-safe materials, Kelpi aims to provide environmentally friendly alternatives that help eliminate single-use plastics, promoting sustainability in packaging practices.

Lightox specializes in developing advanced molecular tools for imaging, therapeutics, and assay development, focusing on innovative cancer treatments. The company has created a range of light-activated drug compounds designed to selectively target and eliminate tumor cells while minimizing harm to surrounding healthy tissue. Their unique fluorescent probes are smaller than any other products currently available, allowing for versatile applications in research and clinical settings. These probes can function as freely-moving agents that easily integrate into cells, or they can be customized with flexible linkers to meet specific research requirements. Lightox aims to enhance patient outcomes by providing more efficient cancer treatment options.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

Multus is a London-based company established in 2019 that specializes in providing affordable and efficient growth media for the cultivated meat industry. By employing a machine learning approach, Multus develops entirely animal-free growth media tailored specifically for animal cells, helping cultivated meat companies scale their production while maintaining high performance. The company focuses on optimizing growth factor proteins produced by genetically engineered microorganisms, thereby eliminating the environmental drawbacks associated with traditional animal serum-based media. This innovative solution supports the growth of diverse animal cell types and tissues, enabling clients to produce sustainable meat products while minimizing the environmental and economic impacts of conventional meat production.

Concert Bio helps businesses create optimal microbial communities.

The National Biofilms Innovation Centre (NBIC) is the central hub where academia, industry, government, and public policy come together to tackle the grand challenges biofilms present, impacting ~$5 trillion in global economic activity, from food and health to ships, clean water and energy. Funded by the BBSRC, Innovate UK and Hartree Centre, our mission is to establish a network of research and innovation capacity to catalyse partnerships with industry to achieve breakthrough innovations and impact – from industry products and solutions to services and spinouts. We aim to bring together researchers and industry to explore unmet needs and exchange ideas, problems and solutions through roadmaps, workshops and conferences. We plan to invest in future scientists through our PhD and Post-Doc programs, and entrepreneurial training, to grow their expertise, help them better understand the commercial environment and encourage new start-ups.

Biome Bioplastics specializes in the production of biodegradable and compostable materials designed to replace traditional oil-based polymers. The company offers a range of bioplastics, including high-temperature non-woven fibers, flexible films, and various coating and lamination products. Their innovative processing techniques encompass injection molding, sheet extrusion for thermoforming, vacuum forming, blown film production, and monofilaments. By focusing on environmentally sustainable solutions, Biome Bioplastics aims to meet the growing demand for eco-friendly materials, providing clients with cost-effective options that enhance both environmental and end-of-life performance.

Vann is a platform for people affected by cancer aiming to help millions of people globally and revolutionize cancer research and care. Vann has been backed by the Oxford University Innovation, Innovate UK, OxLEP European Regional Development Fund, and UK angel investors and is based in the UK.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Adamo Foods is a UK-based food technology company focused on developing plant-based whole-cut meats through innovative fermentation techniques and mycelium. The company aims to produce sustainable alternatives to traditional meat products, utilizing precision fermentation to create functional meat proteins. By harnessing fungal mycelium, Adamo Foods offers consumers an efficient, sustainable, and ethical way to enjoy meat-like experiences without sacrificing taste or quality.

Their management team has extensive experience within the biopharmaceutical industry, and a wealth of knowledge in building successful biotechnology companies. They are developing novel therapeutic antibody approaches to target a fundamental control pathway associated with several major diseases. These novel approaches give aTen Therapeutics the potential to develop powerful new treatments to extend and improve lives.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. Its offerings include induced pluripotent stem cells, human and multispecies primary cells, and a comprehensive cell culture and analysis package. The company utilizes advanced devices such as micro physiological systems and microfluidic designs to enhance drug discovery. One of its notable projects, "Liver on chip," focuses on liver toxicity testing and incorporates techniques like cellular reprogramming and organ-on-chip technology. Stemnovate also offers services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Awakn Life Sciences is a biotechnology company dedicated to developing and delivering psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company's team comprises chemists, scientists, psychiatrists, and psychologists who are working on the next generation of psychedelic drugs and therapies. By addressing AUD, a condition that affects millions worldwide and for which existing treatments are often insufficient, Awakn seeks to provide innovative therapeutic solutions for individuals struggling with addiction.

DeepMirror is a software platform that integrates human expertise with artificial intelligence to enhance drug discovery processes. The company specializes in predicting the properties of molecules and their affinity for various targets, thereby streamlining the research and development efforts of biopharmaceutical teams. By employing structured perception and feature fusion techniques, DeepMirror's platform delivers advanced 3D insights while maintaining low power consumption. This capability simplifies the analysis of complex data, ultimately allowing researchers to focus on the most promising drug candidates and conduct fewer experiments, leading to more efficient drug development.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

From commercially grown crops to agroforestry, from seed to harvest, track and optimize your plants' growth with ease. Petiole Pro develops innovative tools for its growers community to enable data-driven agriculture, better yields and profits. Try Petiole Pro today and grow smarter.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. The company aims to block the action of the enzyme KMO, which plays a crucial role in regulating systemic inflammation and is implicated in various medical conditions. By providing new therapies that target this key enzyme, Kynos Therapeutics seeks to offer innovative treatments for conditions where there is a significant demand for effective medicines.

PheroSyn develops and produces novel pest pheromones. PheroSyn is a spin-out from Rothamsted Research, the world-leading, non-profit research centre that focuses on strategic agricultural science to the benefit of farmers and society worldwide.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Xampla Ltd is a cleantech company based in Cambridge, United Kingdom, that specializes in developing plant protein-based materials as sustainable alternatives to traditional plastics and microplastics. Founded in 2018, Xampla produces a variety of products, including microcapsules, films, coatings, and beads, which are designed for use in sectors such as food, cosmetics, household products, animal feed, packaging, and medical applications. All materials are biodegradable and biocompatible, made without synthetic ingredients, allowing clients to create environmentally friendly products that minimize pollution.

Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Sixfold Bioscience Inc. focuses on developing innovative drug delivery techniques aimed at treating cancer patients. Founded in 2018 and headquartered in London, the company specializes in programmable oligonucleotide delivery systems that target RNA specifically to diseased cells. This approach enhances the precision and effectiveness of cancer treatments, positioning Sixfold Bioscience as a significant player in the biotechnology sector.

Dyneval specializes in portable technology for the analysis of cattle semen quality. Its innovative system measures semen motility in conditions that closely mimic natural environments, providing valuable insights into sperm behavior. By utilizing dynescan data, Dyneval's technology assists in formulating breeding plans and verifying semen quality throughout the supply chain. This approach aims to enhance livestock production, thereby contributing to food security while also addressing environmental concerns by reducing methane emissions. Ultimately, Dyneval's solutions help farmers minimize losses associated with low conception rates.

PheroSyn develops and produces novel pest pheromones. PheroSyn is a spin-out from Rothamsted Research, the world-leading, non-profit research centre that focuses on strategic agricultural science to the benefit of farmers and society worldwide.

Rinri Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, focused on developing regenerative stem cell-based therapies to treat hearing loss. Founded in 2018, the company specializes in advanced stem cell technology that aims to repair damaged or dead sensory cells in the inner ear, specifically targeting sensorineural hearing loss. By restoring the cytoarchitecture of the inner ear, Rinri Therapeutics seeks to enable medical professionals to effectively restore hearing for affected patients.

CryoLogyx is an early-stage biotechnology company focused on advancing cell cryopreservation technology to enhance drug discovery processes. By employing innovative methods that utilize cryoprotectants, CryoLogyx transforms the freezing, storage, and transportation of cells. This proprietary technology ensures the delivery of viable, ready-to-use cells and cell therapies, allowing healthcare researchers to access these resources in the desired format. The company's approach aims to improve the efficiency and effectiveness of cell-based research in the fields of medicine discovery, diagnostics, and cell therapy.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Glamorous AI develops an artificial intelligence-based drug discovery platform that focuses on low-data scenarios in pharmaceutical research. The platform utilizes AI to identify and optimize novel chemical compounds, facilitating the discovery of new medicines by analyzing prior experimental results. It is designed to handle sparse, noisy, and small datasets, making it particularly effective for tackling complex drug discovery challenges. By leveraging a large repository of pre-trained and customizable AI models, Glamorous AI enables researchers to screen extensive chemical libraries and address novel and first-in-class therapeutic targets, ultimately driving innovation in drug development and contributing to the advancement of treatments for various diseases.

Arecor Limited, based in Cambridge, United Kingdom, specializes in stabilization technology solutions for pharmaceutical and biotech companies. The company collaborates with these firms to enhance the commercial viability and usability of various proteins across multiple applications, including vaccines and therapeutic proteins. Arecor focuses on developing products for infectious diseases, diabetes, oncology, and autoimmune disorders, and aims to create high-concentration therapies that patients can self-administer at home. Notable projects include reformulating antibodies such as Trastuzumab and Rituximab for improved home treatment of breast cancer and non-Hodgkin’s lymphoma, respectively. Additionally, Arecor develops stable liquid formulations for vaccines and therapies that facilitate self-administration, addressing challenges related to stability and degradation. Founded in 2006, Arecor is recognized for its innovative formulation technology platform, which underpins its proprietary product portfolio and partnerships with industry leaders to advance biopharmaceutical development.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Camallergy Limited, based in Cambridge, United Kingdom, is a biopharmaceutical company established in 2015 that focuses on developing and manufacturing oral immunotherapy drugs and other pharmaceutical products specifically for food allergies. The company's primary offering is a novel oral immunotherapy designed to treat peanut allergies, which aims to provide patients with "bite-proof" protection within 14 weeks of therapy. This patient-centric treatment addresses the urgent needs of millions suffering from food allergies and is rooted in clinical research conducted at Cambridge University Hospitals NHS Foundation Trust. Camallergy's unique intellectual property and treatment regimen exemplify its commitment to improving the quality of life for individuals affected by these allergies.

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.

Aramune Technologies focuses on creating natural, plant-derived feed materials that can be integrated with conventional animal feeds to replace antimicrobial agents and foster growth. The company is dedicated to developing infection prevention technologies that offer sustainable alternatives to harmful ingredients in both animal and consumer healthcare products. Through laboratory-scale isolation, Aramune generates a natural, orally available compound that is free of endotoxins and non-toxic. This innovation aims to prevent infections in livestock, companion animals, and humans, thereby helping farmers reduce the incidence of diseases and infections in their animals.

SilviBio is a company focused on enhancing the sustainability of tree growth through innovative seed enhancement technology. It develops products aimed at reducing seed losses, which pose challenges for forestry organizations striving to meet government tree planting goals. By creating a coating for seeds that improves moisture absorption and retention, SilviBio enables growers to achieve higher germination rates, particularly in dry conditions. This technology not only supports forestry efforts but also has applications in the agriculture sector, contributing to improved yield outcomes.

NovaBiotics Ltd. is a clinical-stage biotechnology company based in Aberdeen, United Kingdom, with an additional location in Raleigh, North Carolina. Founded in 2004, the company specializes in the design and development of innovative anti-infective therapies for medically unmet diseases. Its product pipeline includes Novexatin, a cationic antifungal peptide for treating onychomycosis, and Lynovex, a dual-therapy for cystic fibrosis-related lung diseases. Additionally, NovaBiotics offers other antifungal peptides such as Novamycin for conditions like aspergillosis and cryptococcosis, as well as Novarifyn, an antibacterial peptide targeting bacterial infections. The company’s proprietary anti-infective peptide platform allows for the development of both antifungal and antibacterial candidates, addressing serious health challenges related to drug-resistant infections.

Decorte Future Industries is a venture-backed startup focused on utilizing artificial intelligence to extract health data from sound. The company has developed advanced machine-learning methods that enable the extraction of complex biometrics, including cardiovascular and respiratory health, from audio recorded via standard microphones. This innovative approach allows clients to gather intricate health data efficiently and at scale, simplifying the process of health monitoring.

Atelerix Limited, based in Cambridge, United Kingdom, specializes in the storage and transportation of viable cells and tissues at room temperature. Founded in 2006, the company has developed a patented technology that utilizes alginate hydrogels to encapsulate biological products, protecting them from biochemical and physical damage during storage and shipping. This innovative approach eliminates the need for cryopreservation, making it easier for customers to use cells and assays immediately upon arrival without the risk of cytotoxicity or damage. Atelerix's technology enhances predictability and reliability in drug discovery models and cell therapies, allowing for the safe storage and transport of suspended and planted cells, as well as tissues and stem cells.

DIOSynVax is a vaccine antigen design company that focuses on accelerating vaccine development to enhance protection against both existing and emerging pathogens. By utilizing innovative technology, DIOSynVax digitally designs, optimizes, and synthesizes vaccines, leading to significant advancements in immunization against diseases such as influenza, COVID-19, and viral hemorrhagic fevers. The company's approach aims to improve the efficacy of vaccines, enabling healthcare professionals to treat patients more effectively and facilitate quicker recovery from various viral infections.